Elevance Health shares have seen strong momentum with a 22.66% total shareholder return over the past year.
The company is expanding its Health OS data platform and recently signed a deal with CNSide Diagnostics.
Financial models suggest the stock could be 20% undervalued relative to its long-term cash flow potential.
The insurer faces ongoing risks, including rising medical costs and litigation regarding Medicare star ratings.